Use of a next generation maleimide in combination with THIOMAB™ antibody technology delivers a highly stable, potent and near homogeneous THIOMAB™ antibody-drug conjugate (TDC)

Herein we demonstrate that conjugation of a next generation maleimide (NGM) to engineered cysteines in a THIOMAB™ antibody delivers a THIOMAB™ antibody-drug conjugate (TDC) with a drug loading of ca. 2. This TDC is highly stable in blood serum conditions, selective and potent towards HER2 expressing...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	RSC advances 2017-01, Vol.7 (40), p.24828-24832
Hauptverfasser:	Nunes, João P. M., Vassileva, Vessela, Robinson, Eifion, Morais, Maurício, Smith, Mark E. B., Pedley, R. Barbara, Caddick, Stephen, Baker, James R., Chudasama, Vijay
Format:	Artikel
Sprache:	eng
Schlagworte:	Antibodies Biotechnology Blood Conjugates Conjugation Criteria Cysteine Serums
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!